Related Experiment Videos
Immunologic aspects of vigabatrin treatment in epileptic children
R Pacifici1, P Zuccaro, P Iannetti
1Clinical Biochemistry Department, Istituto Superiore di Sanità, Rome, Italy.
Insights
Vigabatrin (VGB), an antiepileptic drug, was studied in children. VGB treatment significantly increased T-suppressor and natural killer (NK) cells and NK cell activity, suggesting immune system modulation.
Area of Science:
- Immunology
- Pharmacology
- Neurology
Background:
- Vigabatrin (VGB) is an antiepileptic drug (AED) that functions by irreversibly inhibiting gamma-aminobutyric acid transaminase (GABA-T).
- Understanding the immunological effects of VGB is crucial for managing epilepsy treatment, especially in pediatric populations.
Purpose of the Study:
- To evaluate the immune responses in epileptic children undergoing treatment with Vigabatrin (VGB).
- To assess changes in lymphocyte subsets, immunoglobulin levels, and natural killer (NK) cell activity during VGB therapy.
Main Methods:
- Studied 29 epileptic children and 15 controls, testing immune parameters before and after 1 and 3 months of VGB treatment.
- Utilized whole blood for antibody subset analysis and peripheral blood mononuclear cells (PBMC) for NK cell activity and lymphocyte proliferation assays.
- Measured serum immunoglobulin (Ig) levels.
Main Results:
- No baseline immunologic abnormalities were found in either group.
- VGB treatment did not alter B lymphocytes, serum Ig levels, total T lymphocytes (CD3), T-rosetting lymphocytes (CD11), T-helper cells (CD4), or lymphocyte mitogenic response.
- Statistically significant increases were observed in T-suppressor cells (CD8), NK cells, and NK cell activity after 1 and 3 months of VGB treatment.
- A significant correlation was noted between NK cell number and NK cell activity.
Conclusions:
- Vigabatrin (VGB) treatment in epileptic children leads to a significant increase in cytotoxic cell populations, specifically T-suppressor (CD8) and NK cells.
- These findings suggest that VGB may modulate the immune system, particularly affecting cytotoxic immune cells.
- Further research is warranted to elucidate the clinical implications of these immunomodulatory effects in epilepsy management.
Abstract:
Vigabatrin (VGB) is an antiepileptic drug (AED) that acts by irreversibly inhibiting gamma-aminobutyric acid transaminase (GABA-T). To evaluate immune responses to GVG, we studied 29 idiopathic or symptomatic epileptic children and also examined a control group (n = 15). Epileptic children were tested before and after 1 and 3 months of VGB treatment. Whole blood was used to connect subsets with commercial monoclonal antibodies. Peripheral blood mononuclear cells (PBMC) were used to assess natural killer (NK) cell activity and lymphocyte response to phytohemagglutinin (PHA) and concavalin A (Con A). Immunoglobulin (Ig) levels were tested in serum. At baseline, no immunologic abnormalities were observed in either control or treated patients. During treatment, the percentage and absolute number of B lymphocytes, serum concentration of Ig, number of T total mature lymphocytes (CD3), T-rosetting lymphocytes (CD11), T-helper cells (CD4), and mitogenic response of lymphocytes remained unchanged. Several other immunologic responses showed a statistically significant increase after 1 and 3 months of VGB treatment, however, including the percentage and absolute number of T-suppressor cells (CD8) and NK cells and NK cell activity. The correlation between number of NK cells and NK cell activity was significant. Data obtained demonstrated that VGB may interfere with the modulation of the immune system, especially cytotoxic cell populations.